AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00459173
Drug: rimonabant (SR141716)
RxNorm normalized name: rimonabant
DrugBank: Rimonabant (DB06155)
FDA approved: no
EMA approved: yes
PMDA approved: no
Trial: NCT00360828
Drug: Irinotecan Hydrochloride (HCI) Treatment
RxNorm normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Irinotecan injections. Irinotecan hydrochloride \[CPT-11; CAMPTOSAR\] is an antineoplastic agent of the topoisomerase I inhibitor class. The drug is supplied in amber vials and appears as a pale yellow transparent aqueous solution. Two vial sizes are available: 2 mL vials containing 40 mg of drug and 5 mL vials containing 100 mg of drug. A treatment cycle was 21 days. Patients were treated for a minimum of 3 cycles (doses) of CPT-11 or until their disease progressed.
Trial: NCT00360828
Drug: Continued Irinotecan Hydrochloride (HCI) Treatment
RxNorm normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: For patients responding to treatment, therapy could have continued beyond 18 cycles.
Trial: NCT01579799
Drug: L-lysine
RxNorm normalized name: L-Lysine
DrugBank: Lysine (DB00123)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dose finding study for L-lysine
Trial: NCT02634307
Drug: ALKS 8700
RxNorm normalized name: ALKS 29
DrugBank: ALKS 29 (DB05723)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm.
Trial: NCT01691716
Drug: Tendoactive
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Food supplement containing mucopolysaccharides, type I collagen and vitamin C
Trial: NCT01056861
Drug: Botulinum Toxin A
RxNorm normalized name: Botulinum toxin A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Not exceeding a total dose of 400 units, once every three months.
Trial: NCT02545283
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive cytarabine 1 gram per square meter (g/m\^2) intravenous (IV) infusion for 5 days of every treatment cycle.
Trial: NCT02545283
Drug: Idasanutlin
RxNorm normalized name: Idasanutlin
DrugBank: Idasanutlin (DB12325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive idasanutlin 300 mg per oral (PO) twice daily (BID) (in Cycle 1) or once daily (QD) (in Cycles 2 and 3) for 5 days of every treatment cycle.
Trial: NCT02581553
Drug: lesinurad/allopurinol 200/300 FDC tablets
DrugBank: Allopurinol (DB00437)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02581553
Drug: lesinurad 200 mg
RxNorm normalized name: lesinurad 200 MG
DrugBank: Lesinurad (DB11560)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02581553
Drug: allopurinol 300 mg
RxNorm normalized name: allopurinol 300 MG
DrugBank: Allopurinol (DB00437)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02581553
Drug: lesinurad/allopurinol 200/200 FDC tablets
DrugBank: Allopurinol (DB00437)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02581553
Drug: allopurinol 200 mg
RxNorm normalized name: allopurinol 200 MG
DrugBank: Allopurinol (DB00437)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01320254
Drug: Cisplatin, Gemcitabine, Panitumumab
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cisplatin 25mq/sq.m. at day 1+8 and Gemcitabine 1000mg/sq.m. at day 1 + 8 Panitumumab 9mg/kg BW at day 1
Trial: NCT01320254
Drug: Cisplatin, Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cisplatin 25mq/sq.m. at day 1+8 and Gemcitabine 1000mg/sq.m. at day 1 + 8
Trial: NCT01808300
Drug: Pregabalin 300mg, Thioctic acid 600mg
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: * A: Pregabalin - Pregabalin 300mg will be administered orally twice a day for 3 days~* B: Thioctic acid - Thioctic acid 600mg will be administered orally once a day for 3 days~* C: Pregabalin plus Thioctic acid - Pregabalin plus Thioctic acid same way as A and B
Trial: NCT00264238
Drug: Memantine
RxNorm normalized name: Memantine
DrugBank: Memantine (DB01043)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: pharmacological dosing of memantine as adjunctive therapy for treatment-resistant obsessive-compulsive disorder
Trial: NCT01720147
Drug: Quercetin (dietary supplement)
DrugBank: Quercetin (DB04216)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quercetin will be given orally on a twice a day schedule starting with weight adjusted dose for a maximum total daily dose of 1500 mg/day, for 4 months (16 weeks). Pharmacokinetics (PK) data will be analyzed after each cohort of 3 patients and will be used to optimize the dosing schedule (if required)for subsequent patients.~An expansion cohort has been added to the study protocol. Up to 20 patients may be enrolled. The dose utilized will be the same as the max weight adjusted dose that showed biological activity in our last cohort of patients (subjects #10-12 from above).
Trial: NCT00716651
Drug: mepolizumab
RxNorm normalized name: Mepolizumab
DrugBank: Mepolizumab (DB06612)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 750 mg mepolizumab iv q4wk until week 32
Trial: NCT01314716
Drug: AZLI
RxNorm normalized name: Bazlitoran
DrugBank: Bazlitoran (DB14990)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZLI 75 mg reconstituted with diluent and administered via nebulizer three times daily
Trial: NCT03312959
Drug: hyperbaric bupvacaine in Peribulbar block
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: hyperbaric bupivacaine in Peribulbar block will be injected in the posterior segment surgery
Trial: NCT03312959
Drug: isobaric bupvacaine in Peribulbar block
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: isobaric bupivacaine in Peribulbar block will be injected in the posterior segment surgery
Trial: NCT00365365
Drug: Doxorubicin and cyclophosphamide (AC) + bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: For every 3-week cycle~* bevacizumab 15 mg/kg infused intravenously (IV) on Day 1 followed by~* doxorubicin 60 mg/m\^2 IV push or infusion followed by cyclophosphamide 600 mg/m\^2 IV push or infusion~* Prophylactic G-CSF was administered within 24 hours following each cycle of chemotherapy but no greater than 72 hours after chemotherapy
Trial: NCT00365365
Drug: Docetaxel (T) + bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: For every 3-week cycle~* bevacizumab 15 mg/kg infused intravenously (IV) on Day 1 followed by~* docetaxel 100 mg/m\^2 IV~* Prophylactic G-CSF was administered within 24 hours following each cycle of chemotherapy but no greater than 72 hours after chemotherapy~Note: The starting dose of docetaxel was reduced to 75 mg/m\^2 if toxicity occurred that met the criteria for doxorubicin dose reduction
Trial: NCT00365365
Drug: Docetaxel, doxorubicin, cyclophosphamide (TAC) + bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: For every 3-week cycle~* bevacizumab 15 mg/kg infused intravenously (IV) on Day 1 followed by~* doxorubicin 50 mg/m\^2 IV push or infusion followed by cyclophosphamide 500 mg/m\^2 IV push or infusion followed by docetaxel 75 mg/m\^2~* Prophylactic G-CSF was administered within 24 hours following each cycle of chemotherapy but no greater than 72 hours after chemotherapy
Trial: NCT00365365
Drug: Docetaxel, carboplatin, trastuzumab (TCH) + bevacizumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: For every 3-week cycle~* bevacizumab 15 mg/kg infused intravenously (IV) on Day 1 followed by~* docetaxel in 75 mg/m\^2 IV followed by carboplatin AUC 6 mg/mL/min IV followed by~* trastuzumab 6 mg/kg by IV infusion (For the first cycle 1 only a loading dose of trastuzumab 8 mg/kg IV was infused on Day 2)~* Prophylactic G-CSF was administered within 24 hours following each cycle of chemotherapy but no greater than 72 hours after chemotherapy
Trial: NCT00365365
Drug: Bevacizumab and trastuzumab maintenance therapy
RxNorm normalized name: Bevacizumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: * bevacizumab 15 mg/kg was infused IV followed by~* trastuzumab 6 mg/kg IV~Treatment was every 3 weeks for 52 weeks from the date of the first administration regardless of the number of doses received or missed.
Trial: NCT01234272
Drug: morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ITM-IVPCA: intrathecal administration of 0.3 mg morphine before induction of general anesthesia and application of IVPCA (basal infusion: fentanyl 0.4mcg/kg/hr, bolus: 0.16mcg/kg of fentanyl with a lock out time of 15 min)
Trial: NCT01234272
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PCEA: epidural administration of 5ml 0.2% ropivacaine before induction of general anesthesia and application of PCEA (basal infusion: 5ml 0.2% ropivacaine with fentanyl 0.4 mcg/kg/hr, bolus: 2ml 0.2% ropivacaine with fentanyl 0.16mcg/kg with a lockout time 15min)
Trial: NCT00700271
Drug: Amlodipine
RxNorm normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 mg or 10 mg tablets.
Trial: NCT00700271
Drug: Valsartan
RxNorm normalized name: Valsartan
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 160 mg capsules.
Trial: NCT00865072
Drug: Metformin HCl 750 mg Extender Release tablets, single dose
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: A: Experimental Subjects received Purepac formulated products under fasting conditions
Trial: NCT00365365
Drug: Bevacizumab maintenance therapy
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: - bevacizumab 15 mg/kg was infused IV~Treatment was every 3 weeks for 52 weeks from the date of the first administration regardless of the number of doses received or missed.
Trial: NCT00754325
Drug: Dasatinib
RxNorm normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tablets, Oral, 100 mg, once daily (QD), upto 2 years
Trial: NCT00754325
Drug: Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intramuscular injection (IM), loading dose (500 mg) on Day 1 followed by 500 mg on Day 15 of Cycle 1. In subsequent cycles, 500 mg IM administered on Day 1. IM day 1 and 15 first cycle then IM Day 1 for all other cycles for 2 years
Trial: NCT00716755
Drug: Risperidone/Olanzapine and PET scans
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Current risperidone/olanzapine users who are 50 or older will be recruited. Dopamine D2 dopamine receptors using a selective D2 dopamine receptor ligand, \[11C\]-raclopride, and plasma levels of risperidone and 9-OH-risperidone, or of olanzapine, and prolactin will be measured on the 1st PET visit. Subsequently, there will be gradual dose reductions of risperidone or olanzapine by 0.5 and 2.5 mg per week, respectively (as long as the total reduction does not exceed 40%). At least 5 days after the termination of the dose taper, participants will have the second PET scan. Participants will be followed up for 24 weeks after the termination of the dose reduction.
Trial: NCT01634555
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 180 milligrams per square meter (mg/m²) administered IV on Day 1 of each cycle
Trial: NCT01634555
Drug: Folinic acid
RxNorm normalized name: Folinic acid
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400 mg/m² administered IV on Day 1 of each cycle
Trial: NCT01634555
Drug: 5-Fluorouracil
RxNorm normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400 mg/m² bolus over 2 to 4 minutes administered IV on Day 1 of each cycle, followed by 2400 mg/m² administered IV over 46 to 48 hours on Days 1 and 2 of each cycle
Trial: NCT01380431
Drug: Lisinopril
RxNorm normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets, 40 mg, single oral dose
Trial: NCT01380431
Drug: lisinopril
RxNorm normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets, 40 mg, single, oral dose
Trial: NCT01380431
Drug: Lisinopril
RxNorm normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50% of subjects received the Par formulated product.
Trial: NCT00643643
Drug: Maraviroc (UK-427,857)
RxNorm normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 mg oral tablet once daily for 10 days
Trial: NCT00643643
Drug: Maraviroc (UK-427,857)
RxNorm normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg oral tablet twice daily for 10 days
Trial: NCT00643643
Drug: Maraviroc (UK-427,857)
RxNorm normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg oral tablet twice daily for 10 days
Trial: NCT00643643
Drug: Maraviroc (UK-427,857)
RxNorm normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 300 mg oral tablet twice daily for 10 days
Trial: NCT04736186
Drug: Loperamide
RxNorm normalized name: Loperamide
DrugBank: Loperamide (DB00836)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Loperamide 4 mg， t.i.d.(d 1-7);4 mg, b.i.d.(d 8-21)
Trial: NCT04736186
Drug: Loperamide and golden bifid
RxNorm normalized name: Golden Eye
DrugBank: Loperamide (DB00836)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients with secondary prevention will be randomly assigned to B：Loperamide 4 mg， t.i.d.(d 1-7);4 mg, b.i.d.(d 8-21)+golden bifid 2 g t.i.d.
Trial: NCT04736186
Drug: Loperamide and montmorillonite powder
RxNorm normalized name: Montmorillonite
DrugBank: Loperamide (DB00836)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients with secondary prevention will be randomly assigned to D：Loperamide 4 mg， t.i.d.(d 1-7);4 mg, b.i.d.(d 8-21)+montmorillonite powder 3 g t.i.d.
Trial: NCT02201407
Drug: Peginterferon alfa-2a
RxNorm normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peginterferon alfa-2a treatment according to standard of care, current summary of product characteristics and in line with the local labeling.
Trial: NCT01344876
Drug: OPB-51602
RxNorm normalized name: OPB-111077
DrugBank: OPB-111077 (DB16630)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily during the treatment period
Trial: NCT04994119
Drug: Warfarin
RxNorm normalized name: Warfarin
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Warfarin (Coumadin) 5 mg film coated tablets
Trial: NCT01928381
Drug: AZD5213 + pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Double blind Investigational drug AZD5213 (capsules) given in combination with pregabalin (capsules)
Trial: NCT01928381
Drug: pregabalin capsules
RxNorm normalized name: Pregabalin Capsules
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Double blind pregabalin capsules to match AZD5213 and placebo
Trial: NCT00840866
Drug: cefprozil
RxNorm normalized name: Cefprozil
DrugBank: Cefprozil (DB01150)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500 mg Tablet
Trial: NCT04197115
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous vitamin C (1.5 grams every 6 hours) will be administered for 4 days or until ICU discharge.
Trial: NCT00002827
Drug: dexrazoxane hydrochloride
RxNorm normalized name: Dexrazoxane Hydrochloride
DrugBank: Dexrazoxane (DB00380)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00002827
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00002827
Drug: vincristine sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00128544
Drug: telbivudine
RxNorm normalized name: Telbivudine
DrugBank: Telbivudine (DB01265)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00128544
Drug: valtorcitabine
RxNorm normalized name: Valtorcitabine
DrugBank: Valtorcitabine (DB06187)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02135887
Drug: MB-6
RxNorm normalized name: MBS
DrugBank: Morpholinylmercaptobenzothiazole (DB14202)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6# TID with meal
Trial: NCT00781339
Drug: sodium 2-(dichloroamino)-2-methylpropane-1-sulfonate monohydrate
RxNorm normalized name: 2-bromo-2-methylpropane
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.1% NVC-422 in saline, up to 100 mL, Study Part 1 - once on Day 1 held in the bladder for 1 hour; Study Part 2 (Part 2a - 0.1% NVC-422, Part 2b - 0.2% NVC-422), once daily for 7 days, held in the bladder for 1 hour
Trial: NCT03804749
Drug: suramin sodium
RxNorm normalized name: Suramin sodium
DrugBank: Suramin (DB04786)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The trial will start from the low dose (10mg/kg) group, followed by the middle dose (15mg/kg) and high dose (20mg/kg) groups, only after the safety in the previous dose group has been demonstrated.。
Trial: NCT00653003
Drug: Leflunomide
RxNorm normalized name: Leflunomide
DrugBank: Leflunomide (DB01097)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tablets, 20mg, single-dose
Trial: NCT00653003
Drug: ARAVA
RxNorm normalized name: Arava
DrugBank: Leflunomide (DB01097)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets, 20mg, single-dose
Trial: NCT00573443
Drug: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg
RxNorm normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dextromethorphan hydrobromide (DM) and quinidine sulfate (Q) capsules (AVP-923 capsules), containing DM 20 mg/ Q 10 mg, taken once daily for 1 week and then twice daily for 11 consecutive weeks to complete a 12-week period
Trial: NCT00573443
Drug: dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg
RxNorm normalized name: dextromethorphan hydrobromide / quinidine sulfate Pill
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dextromethorphan hydrobromide (DM) and quinidine sulfate (Q) capsules (AVP-923 capsules), containing DM 30 mg/ Q 10 mg taken once daily for 1 week and then twice daily for 11 consecutive weeks to complete a 12-week period
Trial: NCT00905606
Drug: Topiramate Tablets
RxNorm normalized name: Topiramate Tablets
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03039426
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5% bupivacaine 20ml divided in two; 10 ml intraperitoneal infiltration and 10 ml subcutaneous infiltration
Trial: NCT00562588
Drug: Aggrenox bid (ASA 25mg/Dipyridamole ER 200mg)
RxNorm normalized name: aspirin 25 MG / dipyridamole 200 MG [Aggrenox]
DrugBank: Dipyridamole (DB00975)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00562588
Drug: ASA 100 mg qd
RxNorm normalized name: aspirin 100 MG
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01770132
Drug: porfimer sodium
RxNorm normalized name: Porfimer Sodium
DrugBank: Porfimer sodium (DB00707)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01770132
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01564862
Drug: vortioxetine (Lu AA21004)
RxNorm normalized name: Vortioxétine
DrugBank: Vortioxetine (DB09068)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lu AA21004 capsules
Trial: NCT01564862
Drug: Duloxetine
RxNorm normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Duloxetine capsules
Trial: NCT03809611
Drug: UNR844-Cl
RxNorm normalized name: CHLORIDE
DrugBank: Chloride ion (DB14547)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5% Ophthalmic solution for topical ocular administration
Trial: NCT00400595
Drug: Mupirocin ointment
RxNorm normalized name: Mupirocin Ointment
DrugBank: Mupirocin (DB00410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: topical ointment (already in widespread clinical use)
Trial: NCT00400595
Drug: Polysporin Triple
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01262690
Drug: PF-05230901
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single ascending doses of PF-05230901 in separate cohorts of subjects; each cohort consists of 6 subjects treated with PF-05230901 and 3 subjects treated with placebo.
Trial: NCT01262690
Drug: PF-05230901
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose SC
Trial: NCT01889004
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Escalating concentrations until loss of responsiveness
Trial: NCT01889004
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Escalating concentrations until loss of responsiveness
Trial: NCT02193074
Drug: nusinersen
RxNorm normalized name: Nusinersen
DrugBank: Nusinersen (DB13161)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered by intrathecal (IT) injection as specified in the treatment arm.
Trial: NCT02997761
Drug: Ibrutinib
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO